{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T06:29:19Z","timestamp":1785738559814,"version":"3.56.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.phrs.2023.106646","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T12:16:08Z","timestamp":1672920968000},"page":"106646","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["In situ vaccination followed by intramuscular poly-ICLC injections for the treatment of hepatocellular carcinoma in mouse models"],"prefix":"10.1016","volume":"188","author":[{"given":"Meng-Tzu","family":"Weng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Feng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-Yun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chen","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Chuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huei-Chi","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Ling","family":"Chiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ja-Der","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsuan-Shu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Chuan","family":"Sheu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.phrs.2023.106646_bib1","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"New Engl. J. Med."},{"issue":"4","key":"10.1016\/j.phrs.2023.106646_bib2","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"New Engl. J. Med."},{"issue":"1","key":"10.1016\/j.phrs.2023.106646_bib3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol."},{"issue":"10126","key":"10.1016\/j.phrs.2023.106646_bib4","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"10064","key":"10.1016\/j.phrs.2023.106646_bib5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.phrs.2023.106646_bib6","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"New Engl. J. Med."},{"issue":"10088","key":"10.1016\/j.phrs.2023.106646_bib7","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.phrs.2023.106646_bib8","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol."},{"issue":"Suppl 1","key":"10.1016\/j.phrs.2023.106646_bib9","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000481245","article-title":"Immuno-oncology in hepatocellular carcinoma: 2017 update","volume":"93","author":"Kudo","year":"2017","journal-title":"Oncology"},{"issue":"3","key":"10.1016\/j.phrs.2023.106646_bib10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2023.106646_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.phrs.2023.106646_bib12","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1158\/1078-0432.CCR-14-1860","article-title":"Immune escape mechanisms as a guide for cancer immunotherapy","volume":"21","author":"Beatty","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2023.106646_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.650486","article-title":"In situ vaccination as a strategy to modulate the immune microenvironment of hepatocellular carcinoma","volume":"12","author":"Lurje","year":"2021","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.phrs.2023.106646_bib14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2023.106646_bib15","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/jitc-2020-001095","article-title":"Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and\/or palliative radiation therapy in patients with advanced solid tumors","volume":"8","author":"Siu","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"12","key":"10.1016\/j.phrs.2023.106646_bib16","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1158\/1078-0432.CCR-18-3997","article-title":"Phase I immunotherapy trial with two chimeric HER-2 B-cell peptide vaccines emulsified in montanide ISA 720VG and Nor-MDP adjuvant in patients with advanced solid tumors","volume":"25","author":"Bekaii-Saab","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.phrs.2023.106646_bib17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1667\/RR13617.1","article-title":"An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 2. Tumor-specific immunity and cure after radio-inducible suicide gene therapy and systemic CD40-ligand and Flt3-ligand gene therapy in an orthotopic tumor model","volume":"182","author":"Kawashita","year":"2014","journal-title":"Radiat. Res."},{"issue":"1","key":"10.1016\/j.phrs.2023.106646_bib18","doi-asserted-by":"crossref","first-page":"4801","DOI":"10.1038\/s41467-019-12794-2","article-title":"Oncolytic adenovirus programmed by synthetic gene circuit for cancer immunotherapy","volume":"10","author":"Huang","year":"2019","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.phrs.2023.106646_bib19","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/s41591-019-0410-x","article-title":"Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination","volume":"25","author":"Hammerich","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2023.106646_bib20","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-022-03144-1","article-title":"Interleukin-12 as an in situ cancer vaccine component: a review","author":"Cheng","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"issue":"4S","key":"10.1016\/j.phrs.2023.106646_bib21","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ucl.2020.10.003","article-title":"Double-stranded RNA immunomodulators in prostate cancer","volume":"47","author":"Salazar","year":"2020","journal-title":"Urol. Clin. North Am."},{"key":"10.1016\/j.phrs.2023.106646_bib22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2147\/JHC.S136652","article-title":"A Phase I trial using local regional treatment, nonlethal irradiation, intratumoral and systemic polyinosinic-polycytidylic acid polylysine carboxymethylcellulose to treat liver cancer: in search of the abscopal effect","volume":"4","author":"de la Torre","year":"2017","journal-title":"J. Hepatocell. Carcinoma"},{"issue":"12","key":"10.1016\/j.phrs.2023.106646_bib23","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1084\/jem.20111171","article-title":"Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans","volume":"208","author":"Caskey","year":"2011","journal-title":"J. Exp. Med."},{"issue":"9","key":"10.1016\/j.phrs.2023.106646_bib24","first-page":"530","article-title":"Poly I:C-induced tumor cell apoptosis mediated by pattern-recognition receptors","volume":"27","author":"Zhao","year":"2012","journal-title":"Cancer Biother Radiopharm."},{"issue":"1","key":"10.1016\/j.phrs.2023.106646_bib25","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s40425-019-0568-2","article-title":"Immunotherapeutic effects of intratumoral nanoplexed poly I:C","volume":"7","author":"Aznar","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.phrs.2023.106646_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2020.101414","article-title":"Poly-ICLC, a multi-functional immune modulator for treating cancer","author":"Sultan","year":"2020","journal-title":"Semin Immunol."},{"key":"10.1016\/j.phrs.2023.106646_bib27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/jitc-2020-001224","article-title":"Poly-IC enhances the effectiveness of cancer immunotherapy by promoting T cell tumor infiltration","volume":"8","author":"Sultan","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"8","key":"10.1016\/j.phrs.2023.106646_bib28","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1158\/2326-6066.CIR-14-0024","article-title":"Therapeutic in situ autovaccination against solid cancers with intratumoral poly-ICLC: case report, hypothesis, and clinical trial","volume":"2","author":"Salazar","year":"2014","journal-title":"Cancer Immunol. Res"},{"issue":"20","key":"10.1016\/j.phrs.2023.106646_bib29","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1158\/1078-0432.CCR-17-1866","article-title":"Therapeutic immune modulation against solid cancers with intratumoral Poly-ICLC: a pilot trial","volume":"24","author":"Kyi","year":"2018","journal-title":"Clin. Cancer Res"},{"issue":"5","key":"10.1016\/j.phrs.2023.106646_bib30","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00262-011-1132-1","article-title":"Roles of the PI3K\/Akt pathway and autophagy in TLR3 signaling-induced apoptosis and growth arrest of human prostate cancer cells","volume":"61","author":"Harashima","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"issue":"29","key":"10.1016\/j.phrs.2023.106646_bib31","doi-asserted-by":"crossref","first-page":"27252","DOI":"10.18632\/oncotarget.4583","article-title":"TLR3 agonist and sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression","volume":"6","author":"Ho","year":"2015","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.phrs.2023.106646_bib32","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","article-title":"Detection of immunogenic cell death and its relevance for cancer therapy","volume":"11","author":"Fucikova","year":"2020","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.phrs.2023.106646_bib33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000282062","article-title":"The role of chemokines in the recruitment of lymphocytes to the liver","volume":"28","author":"Oo","year":"2010","journal-title":"Dig. Dis."},{"issue":"11","key":"10.1016\/j.phrs.2023.106646_bib34","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.trecan.2018.09.001","article-title":"The role of type 1 conventional dendritic cells in cancer iImmunity","volume":"4","author":"Bottcher","year":"2018","journal-title":"Trends Cancer"},{"key":"10.1016\/j.phrs.2023.106646_bib35","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.3389\/fimmu.2019.01312","article-title":"CD83: activation marker for antigen presenting cells and its therapeutic potential","volume":"10","author":"Li","year":"2019","journal-title":"Front Immunol."},{"key":"10.1016\/j.phrs.2023.106646_bib36","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3389\/fimmu.2012.00274","article-title":"Regulatory dendritic cells: there is more than just immune activation","volume":"3","author":"Schmidt","year":"2012","journal-title":"Front Immunol."},{"key":"10.1016\/j.phrs.2023.106646_bib37","first-page":"111","article-title":"CD28 co-stimulation in T-cell homeostasis: a recent perspective","volume":"4","author":"Beyersdorf","year":"2015","journal-title":"Immun. Ther."},{"issue":"2","key":"10.1016\/j.phrs.2023.106646_bib38","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1189\/jlb.0603252","article-title":"Interferon-gamma: an overview of signals, mechanisms and functions","volume":"75","author":"Schroder","year":"2004","journal-title":"J. Leukoc. Biol."},{"issue":"9","key":"10.1016\/j.phrs.2023.106646_bib39","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/cdd.2012.22","article-title":"dsRNA induces apoptosis through an atypical death complex associating TLR3 to caspase-8","volume":"19","author":"Estornes","year":"2012","journal-title":"Cell Death Differ."},{"issue":"7","key":"10.1016\/j.phrs.2023.106646_bib40","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/carcin\/bgn149","article-title":"Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism","volume":"29","author":"Paone","year":"2008","journal-title":"Carcinogenesis"},{"issue":"6","key":"10.1016\/j.phrs.2023.106646_bib41","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/cdd.2009.190","article-title":"Proapoptotic signalling through Toll-like receptor-3 involves TRIF-dependent activation of caspase-8 and is under the control of inhibitor of apoptosis proteins in melanoma cells","volume":"17","author":"Weber","year":"2010","journal-title":"Cell Death Differ."},{"issue":"1","key":"10.1016\/j.phrs.2023.106646_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001759","article-title":"Direct type I IFN but not MDA5\/TLR3 activation of dendritic cells is required for maturation and metabolic shift to glycolysis after poly IC stimulation","volume":"12","author":"Pantel","year":"2014","journal-title":"PLoS Biol."},{"issue":"1","key":"10.1016\/j.phrs.2023.106646_bib43","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s13046-021-02017-2","article-title":"A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy","volume":"40","author":"De Waele","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.phrs.2023.106646_bib44","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/s41590-018-0145-8","article-title":"Adjustment of dendritic cells to the breast-cancer microenvironment is subset specific","volume":"19","author":"Michea","year":"2018","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.phrs.2023.106646_bib45","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","article-title":"Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition","volume":"44","author":"Salmon","year":"2016","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.phrs.2023.106646_bib46","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1500109","article-title":"Enhancing the immune stimulatory effects of cetuximab therapy through TLR3 signalling in Epstein-Barr virus (EBV) positive nasopharyngeal carcinoma","volume":"7","author":"Tan","year":"2018","journal-title":"Oncoimmunology"},{"issue":"7","key":"10.1016\/j.phrs.2023.106646_bib47","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1084\/jem.20090247","article-title":"Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant","volume":"206","author":"Longhi","year":"2009","journal-title":"J. Exp. Med."},{"issue":"5","key":"10.1016\/j.phrs.2023.106646_bib48","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1426434","article-title":"Bufalin suppresses migration and invasion of hepatocellular carcinoma cells elicited by Poly (I:C) therapy","volume":"7","author":"Feng","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.phrs.2023.106646_bib49","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1186\/1471-2407-13-527","article-title":"A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo","volume":"13","author":"Xu","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.phrs.2023.106646_bib50","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1146\/annurev-immunol-051116-052215","article-title":"Antigen-presenting cells in the skin","volume":"35","author":"Kashem","year":"2017","journal-title":"Annu. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.phrs.2023.106646_bib51","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/0008-5472.1089.65.3","article-title":"Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity","volume":"65","author":"Hirano","year":"2005","journal-title":"Cancer Res."},{"issue":"305","key":"10.1016\/j.phrs.2023.106646_bib52","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1259\/0007-1285-26-305-234","article-title":"Whole body irradiation; radiobiology or medicine?","volume":"26","author":"Mole","year":"1953","journal-title":"Br. J. Radiol."},{"issue":"15","key":"10.1016\/j.phrs.2023.106646_bib53","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1158\/0008-5472.CAN-16-2165","article-title":"Immune checkpoint blockade, immunogenic chemotherapy or IFN-alpha blockade boost the local and abscopal effects of oncolytic virotherapy","volume":"77","author":"Fend","year":"2017","journal-title":"Cancer Res."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661823000026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661823000026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:40:11Z","timestamp":1760913611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661823000026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":53,"alternative-id":["S1043661823000026"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2023.106646","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In situ vaccination followed by intramuscular poly-ICLC injections for the treatment of hepatocellular carcinoma in mouse models","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2023.106646","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106646"}}